by Fred Dumais | Sep 27, 2023 | News Release
MONTREAL, QUEBEC , September 27, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it has entered into a credit facility agreement with Accord Financial Inc. The $5 million...
by Fred Dumais | Sep 13, 2023 | Communiqué de presse
Septième trimestre consécutif de croissance des revenus à 14.1 millions $ au T3-2023, en hausse de 132% par rapport au T3-2022 Le nombre de médecins prescrivant Enerzair et Atectura a atteint 2 503 à la fin du T3-2023, soit une croissance de 23 % par rapport au...
by Fred Dumais | Sep 13, 2023 | News Release
Seventh consecutive quarter of revenue growth at $14.1 million in Q3-23, up 132% over Q3-22. Physicians prescribing Enerzair and Atectura reached 2,503 at the end of Q3-23, representing a 23% increase from the prior quarter and a 221% rise year-over-year Total...
by Fred Dumais | Sep 7, 2023 | Communiqué de presse
MONTRÉAL (QUÉBEC), le 7 septembre 2023 – Valeo Pharma inc. (TSX : VPH, OTCQB : VPHIF, FSE : VP2) (la « Société » ou « Valeo Pharma »), une société pharmaceutique canadienne, a annoncé aujourd’hui qu’elle divulguera ses résultats financiers...
by Fred Dumais | Sep 7, 2023 | News Release
MONTREAL, QUEBEC , September 7, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the third quarter ended July 31, 2023...
